前列腺癌诊断中MRI是否需联合标准穿刺?近五年综述
该综述检索截至2018年1月24日的MEDLINE/PubMed文献,纳入34项同时行MRI和标准穿刺的研究,覆盖活检初治、既往阴性穿刺和适合主动监测的既往阳性穿刺三类人群。结果显示MRI靶向穿刺在全部三组中均能更多检出临床显著前列腺癌并减少临床不显著癌检出,但MRI阴性者系统穿刺仍可检出0–20%的临床显著癌。
要点
- MRI靶向穿刺在MRI阳性者中检出临床显著癌效率高于标准穿刺。
- MRI阴性者系统穿刺仍可检出0–20%的临床显著前列腺癌。
- 靶向穿刺减少临床不显著前列腺癌的检出。
核心结论
- MRI靶向穿刺在MRI阳性者中检出临床显著疾病效率高于标准穿刺,并减少临床不显著癌检出。
- MRI阴性者中仍有显著少数可在系统穿刺中检出临床显著癌。
研究设计与样本
- 电子检索MEDLINE/PubMed截至2018年1月24日,检索词含前列腺癌、MRI、活检初治、主动监测、既往阴性穿刺等。
- 仅纳入同时报告标准穿刺与MRI靶向穿刺检出率、且所有受试者均行MRI和标准穿刺的研究。
- 共纳入34篇文章:活检初治14篇、既往阴性穿刺10篇、既往阳性穿刺10篇。
主要发现
- MRI靶向穿刺在全部三类人群中均更多检出临床显著前列腺癌、更少检出临床不显著前列腺癌。
- 该效应在至少一次既往阴性穿刺者中最明显,在主动监测者中最不明显。
- MRI阴性时,系统穿刺检出临床显著前列腺癌的比例范围为0至20%。
关键数值与推荐
- MRI阴性者系统穿刺检出临床显著前列腺癌范围为0–20%。
临床怎么用
- 对MRI阳性者优先采用MRI靶向穿刺以提高临床显著癌检出效率。
- 对MRI阴性者不应完全省略系统穿刺,因仍可能检出临床显著癌。
局限性
- 仅纳入同时行MRI和标准穿刺并报告两者检出率的研究,可能限制外推性。
- 检索截止2018年1月24日,未涵盖此后证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In recent years, evidence has accrued to support the introduction of multiparametric magnetic resonance imaging (mpMRI) in the prostate cancer diagnostic pathway. The exact role of mpMRI in different settings is not widely agreed. In this review, we look at the use of MRI in three groups of men: biopsy naive men, those with a previous negative biopsy and those with a previous positive biopsy suitable for active surveillance. MATERIAL AND METHODS: An electronic MEDLINE/PubMed search up to 24th January 2018 was performed, using the search terms (prostate cancer OR prostate adenocarcinoma) AND (MRI OR magnetic resonance) AND (biopsy naive OR active surveillance OR prior negative biopsy OR no prior biopsy). Only those studies which reported detection rates of standard biopsy and MRI-targeted biopsy, where all men had both an MRI and standard biopsy were included. RESULTS: In total 34 articles were included (14 biopsy naive, 10 prior negative biopsy, and 10 prior positive biopsy). MRI-targeted biopsy consistently resulted in greater detection of clinically significant prostate cancer, and a lower detection of clinically insignificant prostate cancer, across all three patient populations. This effect was most prominent in men with at least one previous negative biopsy, and least prominent in men on active surveillance. In the presence of a negative mpMRI detection of csPCa found at systematic biopsy ranged from 0 to 20%. CONCLUSIONS: MRI-targeted biopsy is more efficient than standard biopsy in detecting clinically significant disease in men with a positive MRI, and results in less detection of clinically insignificant cancer. In men with a negative MRI, a significant minority of men will have clinically significant cancer detected on systematic biopsy.
引用
- Stabile A, Giganti F, Emberton M, et al. MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years. Prostate Cancer Prostatic Dis. 2018. PMID: 30104656. doi:10.1038/s41391-018-0071-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。